Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) Other Operating Expenses (2024 - 2025)

Silence Therapeutics (SLN) has disclosed Other Operating Expenses for 2 consecutive years, with -$20.7 million as the latest value for Q2 2025.

  • Quarterly Other Operating Expenses fell 11.03% to -$20.7 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was -$42.9 million through Dec 2025, down 22.34% year-over-year, with the annual reading at -$113.6 million for FY2024, 20.53% down from the prior year.
  • Other Operating Expenses hit -$20.7 million in Q2 2025 for Silence Therapeutics, up from -$22.2 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of -$16.5 million in Q1 2024 to a low of -$22.2 million in Q1 2025.